Clinical trial
Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial
NCT05778617 is registered in ClinicalTrials.gov with University College, London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial
- Lead sponsor
- University College, London
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 25, 2025
- Completion date
- September 30, 2029
- Enrollment
- 330 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.